Vor Biopharma Announces Board and Compensation Changes
Ticker: VOR · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
TL;DR
Vor Bio's board is shaking up: new directors in, exec comp adjusted.
AI Summary
Vor Biopharma Inc. announced on January 6, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect the company's direction and stability.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- January 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140 (address) — Principal Executive Offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates changes in 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers' but does not specify the exact roles in this summary section.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 6, 2025.
What is Vor Biopharma Inc.'s primary business classification?
Vor Biopharma Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
Where are Vor Biopharma Inc.'s principal executive offices located?
The principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140.
What other items are being reported in this 8-K filing besides director and officer changes?
This 8-K also includes information on 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
Filing Stats: 1,110 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2025-01-08 09:06:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $40,000 — lir will receive a cash retainer fee of $40,000 for service as a director, payable in e
Filing Documents
- d861124d8k.htm (8-K) — 31KB
- d861124dex991.htm (EX-99.1) — 9KB
- g861124dsp5.jpg (GRAPHIC) — 3KB
- g861124g80s62.jpg (GRAPHIC) — 3KB
- 0001193125-25-003259.txt ( ) — 178KB
- vor-20250106.xsd (EX-101.SCH) — 3KB
- vor-20250106_lab.xml (EX-101.LAB) — 18KB
- vor-20250106_pre.xml (EX-101.PRE) — 11KB
- d861124d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2025 Vor Biopharma Inc. By: /s/ Robert Ang Name: Robert Ang Title: Chief Executive Officer